002349 Stock Overview
Engages in the research and development, manufacture, and sale of APIs and pharmaceutical intermediates in China.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Jinghua Pharmaceutical Group Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥7.01 |
| 52 Week High | CN¥10.88 |
| 52 Week Low | CN¥5.88 |
| Beta | 0.032 |
| 11 Month Change | 7.52% |
| 3 Month Change | -13.78% |
| 1 Year Change | -32.98% |
| 33 Year Change | 21.70% |
| 5 Year Change | 33.78% |
| Change since IPO | 109.05% |
Recent News & Updates
Jinghua Pharmaceutical Group (SZSE:002349) Could Easily Take On More Debt
Aug 07
Jinghua Pharmaceutical Group's (SZSE:002349) Upcoming Dividend Will Be Larger Than Last Year's
Jun 07Shareholder Returns
| 002349 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 3.9% | 6.4% | 0.4% |
| 1Y | -33.0% | -10.6% | -21.0% |
Return vs Industry: 002349 underperformed the CN Pharmaceuticals industry which returned -10.6% over the past year.
Return vs Market: 002349 underperformed the CN Market which returned -21% over the past year.
Price Volatility
| 002349 volatility | |
|---|---|
| 002349 Average Weekly Movement | 3.8% |
| Pharmaceuticals Industry Average Movement | 5.1% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in CN Market | 9.0% |
| 10% least volatile stocks in CN Market | 3.8% |
Stable Share Price: 002349 has not had significant price volatility in the past 3 months.
Volatility Over Time: 002349's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1957 | 1,493 | Yunzhong Zhou | www.jinghuapharm.com |
Jinghua Pharmaceutical Group Co., Ltd. engages in the research and development, manufacture, and sale of APIs and pharmaceutical intermediates in China. Its primary products include Phenylbutazone, Primidone, Phenobarbital, Fluorouracil, Propylthiouracil, Piroxicam, and Flucytosine APIs. The company was formerly known as Nantong Jinghua Pharmaceutical Co., Ltd.
Jinghua Pharmaceutical Group Co., Ltd. Fundamentals Summary
| 002349 fundamental statistics | |
|---|---|
| Market cap | CN¥5.72b |
| Earnings (TTM) | CN¥231.11m |
| Revenue (TTM) | CN¥1.46b |
24.7x
P/E Ratio3.9x
P/S RatioIs 002349 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002349 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.46b |
| Cost of Revenue | CN¥755.45m |
| Gross Profit | CN¥707.07m |
| Other Expenses | CN¥475.96m |
| Earnings | CN¥231.11m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 28, 2024
| Earnings per share (EPS) | 0.28 |
| Gross Margin | 48.35% |
| Net Profit Margin | 15.80% |
| Debt/Equity Ratio | 0.7% |
How did 002349 perform over the long term?
See historical performance and comparison